Bank of America Corp
Change company Symbol lookup
Select an option...
BAC Bank of America Corp
BHV BlackRock Virginia Municipal Bond Trust
JNJ Johnson & Johnson
TRQ Turquoise Hill Resources Ltd
STAA STAAR Surgical Co
PRPL Purple Innovation Inc
INTC Intel Corp
PSB PS Business Parks Inc
GWRE Guidewire Software Inc
UYM.TC ProShares Ultra Basic Materials ETF
Go

Financials : Banks | Large Cap Value
Company profile

Bank of America Corporation is a bank holding company and a financial holding company. The Company is a financial institution, serving individual consumers and others with a range of banking, investing, asset management and other financial and risk management products and services. The Company, through its banking and various non-bank subsidiaries, throughout the United States and in international markets, provides a range of banking and non-bank financial services and products through four business segments: Consumer Banking, which comprises Deposits and Consumer Lending; Global Wealth & Investment Management, which consists of two primary businesses: Merrill Lynch Global Wealth Management and U.S. Trust, Bank of America Private Wealth Management; Global Banking, which provides a range of lending-related products and services; Global Markets, which offers sales and trading services, and All Other, which consists of equity investments, residual expense allocations and other.

Closing Price
$24.90
Day's Change
0.03 (0.12%)
Bid
--
Ask
--
B/A Size
--
Day's High
25.26
Day's Low
24.71
Volume
(Below Average)
Volume:
51,007,411

10-day average volume:
60,060,344
51,007,411

Eli Lilly and Amgen to collaborate on COVID-19 antibody therapies

6:41 am ET September 17, 2020 (MarketWatch)
Print

Eli Lilly and Co. (LLY) and Amgen Inc. (AMGN) said Thursday they will collaborate on COVID-19 antibody treatments as a way to significantly boost global supply capacity. The announcement comes a day after Lilly said interim data from a mid-stage clinical trial assessing its experimental antibody treatment reduced the rate of hospitalization as well as viral load in some COVID-19 patients. The investigational therapy, LY-CoV555, is produced using neutralizing antibodies gathered from patients who have recovered from COVID-19. The ongoing, randomized, double-blind, placebo-controlled Phase 2 study is expected to enroll a total of 800 participants, all of whom have mild to moderate symptoms and are being treated with LY-CoV555 in an outpatient setting. Lilly said the rate of hospitalization and emergency room visit was 1.7% for patients taking the drug, while the rate of hospitalization and ER visits for patients taking the placebo was 6.0%. "The results reinforce our conviction that neutralizing antibodies can help in the fight against COVID-19," Dr. Daniel Skovronsky, Lilly's chief scientific officer, said in a news release. The full data is expected to be published in a peer-reviewed journal. "Through this collaboration, the two companies will have the ability to quickly scale up production and serve many more patients around the world should one or more of Lilly's antibody therapies prove successful in clinical testing and receive regulatory approval," Lilly and Agmen said in a joint statement. Lilly shares were slightly higher premarket, while Amgen was down 0.5%.

-Ciara Linnane; 415-439-6400; AskNewswires@dowjones.com

(END) Dow Jones Newswires

September 17, 2020 06:41 ET (10:41 GMT)

Copyright (c) 2020 Dow Jones & Company, Inc.

Earnings Calendar and Events Data provided by |Terms of Use| © 2020 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

Information and news provided by ,, , Computrade Systems, Inc., , and

Copyright © 2020. All rights reserved.